Revisiting Cost-Effectiveness of Commercial or Traditional Fecal Microbiota Transplantation to Prevent Clostridioides difficile Recurrence

This publication has 12 references indexed in Scilit:

• Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
  Drugs, 2022
• SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
  New England Journal of Medicine, 2022
• The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
  The Lancet Regional Health - Europe, 2021
• Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
  Gastroenterology, 2021
• Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis
  eClinicalMedicine, 2020
• Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes
  New England Journal of Medicine, 2020
• Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection
  Alimentary Pharmacology & Therapeutics, 2017
• Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial
  Clinical Infectious Diseases, 2016
• Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach
  BMC Infectious Diseases, 2016
• Duodenal Infusion of Donor Feces for RecurrentClostridium difficile
  New England Journal of Medicine, 2013